Matthew J. Sill focuses his practice on pharmaceutical and medical device mass torts, catastrophic personal injury, wrongful death, and class action litigation. He is frequently selected for leadership positions among large groups of attorneys representing hundreds or thousands of injured parties. Matt currently represents over 75 cities, counties, and tribes in the nationwide opioid litigation, In Re: National Prescription Opiate Litigation, MDL No. 2804, Case No. 17-md-02804. Matt also recently filed the first case in Oklahoma regarding the marketing and sale of JUUL, In Re: Juul Labs, Inc. Marketing, Sales Practices, and Product Liability Litigation.
Matt regularly accepts invitations for faculty positions and speaking engagements at seminars and continuing legal education programs. He has lectured in numerous locations, including Arizona, Florida, Georgia, Illinois, Louisiana, New York, Oklahoma, Puerto Rico, and Texas, with programs typically being attended by lawyers from several other jurisdictions. He was chosen to co-chair HarrisMartin Publishing’s 2013 CAT Flood and Windstorm Litigation Conference. In the practice area of pharmaceutical and medical device litigation, Matt has been a featured instructor or moderator at educational programs devoted to Actos®, GranuFlo®, Topamax®, pre-emption in generic drug cases, and several other topics. He authors a number of articles, and up-to-date information on relevant publications and published legal opinions are available by request from admin@fulmersill.com.
Representing plaintiffs with cases pending in several different jurisdictions, Matt’s ability to practice pro hac vice is often based on the recommendation and sponsorship of local attorneys. See; e.g., MDL 2244, In Re: DePuy Hip Implant Litigation; MDL 2738, In Re: Johnson & Johnson Talcum Powder Products Liability Litigation. He is fully admitted to practice in the State of Oklahoma (2007), where out-of-state lawyers often retain him as local counsel for high-profile matters ranging from product liability to securities and antitrust. See; e.g., In Re: Chesapeake Energy Derivative Litigation. Matt has successfully helped families and individuals involved in opioid litigation, diabetes drug litigation, birth control litigation, gadolinium-based contrast dye litigation, hip replacement litigation, fentanyl pain patch litigation, heart defibrillator lead litigation, Las Vegas hepatitis litigation, Chinese drywall litigation, hormone replacement therapy litigation, denture cream litigation, heart surgery products litigation, dialysis products litigation, and aircraft crash litigation, to mention only a few.
